...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Prognostic Value of Hematological Parameters in Locally Advanced Cervical Cancer Patients Treated With Concurrent Chemoradiotherapy
【24h】

Prognostic Value of Hematological Parameters in Locally Advanced Cervical Cancer Patients Treated With Concurrent Chemoradiotherapy

机译:同时化学疗法治疗局部晚期宫颈癌患者血液学参数的预后价值

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background/Aim: We evaluated the clinical implications of pre- and post-treatment hematological parameters as prognostic factors in patients with locally advanced cervical cancer (LACC) who received definitive concurrent chemoradiotherapy (CCRT). Patients and Methods: We retrospectively analyzed 125 patients with LACC (FIGO stage IIB to IIIB) who received definitive CCRT. Clinical factors and hematological parameters, including neutrophil-to-lymphocyte ratio (NLR) were assessed pre- and post-CCRT. Univariate and multivariate analysis for disease-free survival (DFS) and overall survival (OS) were performed using clinicopathological and hematological parameters. Results: Disease recurred in 46 (36.8%) patients, and 24 patients (19.2%) died. On multivariate analysis, post-treatment NLR, Delta NLR (pre-treatment NLR/post-treatment NLR) and Delta PLR (platelet-to-lymphocyte ratio) (pre-treatment PLR/post-treatment PLR) were significant prognostic factors
机译:背景/目的:我们评估了治疗前后血液学参数的临床意义,作为局部晚期宫颈癌(LACC)的预后因素,接受明确的同步化学疗法(CCRT)。 患者及方法:我们回顾性地分析了125例LACC患者(FIGO Stage IIB至IIIB),他们接受了最终CCRT。 评估临床因素和血液学参数,包括中性粒细胞到淋巴细胞比(NLR)预先和后术后。 使用临床病理学和血液学参数进行无病存活(DFS)和整体存活(OS)的单变量和多变量分析。 结果:46例(36.8%)患者复发的病,24例患者(19.2%)死亡。 在多变量分析中,治疗后NLR,Delta NLR(预处理NLR /后治疗NLR)和DeltaPLR(血小板到淋巴细胞比率)(预处理PLR /后PLR)是显着的预后因素

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号